Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Preferred Stock Liabilities (2016 - 2023)

Historic Preferred Stock Liabilities for Cartesian Therapeutics (RNAC) over the last 3 years, with Q4 2023 value amounting to $296.9 million.

  • Cartesian Therapeutics' Preferred Stock Liabilities changed N/A to $296.9 million in Q4 2023 from the same period last year, while for Dec 2023 it was $296.9 million, marking a year-over-year change of. This contributed to the annual value of $296.9 million for FY2023, which is N/A changed from last year.
  • According to the latest figures from Q4 2023, Cartesian Therapeutics' Preferred Stock Liabilities is $296.9 million.
  • Cartesian Therapeutics' Preferred Stock Liabilities' 5-year high stood at $296.9 million during Q4 2023, with a 5-year trough of $296.9 million in Q4 2023.